to rapidly discover and develop potent, orally available, small molecule inhibitors of the main protease (Mpro) of SARS-CoV-2 using artificial intelligence-driven structure guided drug design
- Funded by Gates Foundation
- Total publications:0 publications
Grant number: INV-031996
Grant search
Key facts
Disease
COVID-19start year
2021Known Financial Commitments (USD)
$767,100Funder
Gates FoundationPrincipal Investigator
N/A
Research Location
United KingdomLead Research Institution
Exscientia AI LimitedResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
N/A
Abstract
N/A